Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce & 16 others Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Original languageEnglish (US)
Pages (from-to)326-362
Number of pages37
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Phosphotransferases
Monoclonal Antibodies
Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., ... Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. JNCCN Journal of the National Comprehensive Cancer Network, 13(3), 326-362. https://doi.org/10.6004/jnccn.2015.0045

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. / Zelenetz, Andrew D.; Gordon, Leo I.; Wierda, William G.; Abramson, Jeremy S.; Advani, Ranjana H.; Andreadis, C. Babis; Bartlett, Nancy; Byrd, John C.; Czuczman, Myron S.; Fayad, Luis E.; Fisher, Richard I.; Glenn, Martha J.; Habermann, Thomas M.; Harris, Nancy Lee; Hoppe, Richard T.; Horwitz, Steven M.; Kelsey, Christopher R.; Kim, Youn H.; Krivacic, Susan; LaCasce, Ann S.; Nademanee, Auayporn; Porcu, Pierluigi; Press, Oliver; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Saad, Ayman A.; Sokol, Lubomir; Swinnen, Lode J.; Tsien, Christina; Vose, Julie M.; Wilson, Lynn; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 3, 01.03.2015, p. 326-362.

Research output: Contribution to journalReview article

Zelenetz, AD, Gordon, LI, Wierda, WG, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Byrd, JC, Czuczman, MS, Fayad, LE, Fisher, RI, Glenn, MJ, Habermann, TM, Harris, NL, Hoppe, RT, Horwitz, SM, Kelsey, CR, Kim, YH, Krivacic, S, LaCasce, AS, Nademanee, A, Porcu, P, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Saad, AA, Sokol, L, Swinnen, LJ, Tsien, C, Vose, JM, Wilson, L, Yahalom, J, Zafar, N, Dwyer, M & Sundar, H 2015, 'Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 3, pp. 326-362. https://doi.org/10.6004/jnccn.2015.0045
Zelenetz, Andrew D. ; Gordon, Leo I. ; Wierda, William G. ; Abramson, Jeremy S. ; Advani, Ranjana H. ; Andreadis, C. Babis ; Bartlett, Nancy ; Byrd, John C. ; Czuczman, Myron S. ; Fayad, Luis E. ; Fisher, Richard I. ; Glenn, Martha J. ; Habermann, Thomas M. ; Harris, Nancy Lee ; Hoppe, Richard T. ; Horwitz, Steven M. ; Kelsey, Christopher R. ; Kim, Youn H. ; Krivacic, Susan ; LaCasce, Ann S. ; Nademanee, Auayporn ; Porcu, Pierluigi ; Press, Oliver ; Rabinovitch, Rachel ; Reddy, Nishitha ; Reid, Erin ; Saad, Ayman A. ; Sokol, Lubomir ; Swinnen, Lode J. ; Tsien, Christina ; Vose, Julie M. ; Wilson, Lynn ; Yahalom, Joachim ; Zafar, Nadeem ; Dwyer, Mary ; Sundar, Hema. / Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 3. pp. 326-362.
@article{7f48579cc1ae4d21bd116d3a9aa2bc81,
title = "Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015",
abstract = "Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.",
author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Wierda, {William G.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Andreadis, {C. Babis} and Nancy Bartlett and Byrd, {John C.} and Czuczman, {Myron S.} and Fayad, {Luis E.} and Fisher, {Richard I.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Harris, {Nancy Lee} and Hoppe, {Richard T.} and Horwitz, {Steven M.} and Kelsey, {Christopher R.} and Kim, {Youn H.} and Susan Krivacic and LaCasce, {Ann S.} and Auayporn Nademanee and Pierluigi Porcu and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Saad, {Ayman A.} and Lubomir Sokol and Swinnen, {Lode J.} and Christina Tsien and Vose, {Julie M.} and Lynn Wilson and Joachim Yahalom and Nadeem Zafar and Mary Dwyer and Hema Sundar",
year = "2015",
month = "3",
day = "1",
doi = "10.6004/jnccn.2015.0045",
language = "English (US)",
volume = "13",
pages = "326--362",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Wierda, William G.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Byrd, John C.

AU - Czuczman, Myron S.

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Harris, Nancy Lee

AU - Hoppe, Richard T.

AU - Horwitz, Steven M.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Nademanee, Auayporn

AU - Porcu, Pierluigi

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Saad, Ayman A.

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Tsien, Christina

AU - Vose, Julie M.

AU - Wilson, Lynn

AU - Yahalom, Joachim

AU - Zafar, Nadeem

AU - Dwyer, Mary

AU - Sundar, Hema

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

AB - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

UR - http://www.scopus.com/inward/record.url?scp=84924370528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924370528&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0045

DO - 10.6004/jnccn.2015.0045

M3 - Review article

VL - 13

SP - 326

EP - 362

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 3

ER -